When it comes to Faron’s investment story, presumably those solid tumor types offer the greatest potential for value appreciation, and I have understood from the Jalkasens’ comments that they are eyeing solid tumors through their work with blood cancers. Bexera offers an opportunity to commercialize Bex and collaborate with BF. However, the main target is further ahead, i.e., in solid tumor types.
Of course, Bexera could fail, but presumably one of those investigator-initiated trials could yield a potential result to build upon. One must admit that a failure of Bexera would certainly complicate Faron’s journey.